• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Braeden Lichti

    10/17/24 4:05:15 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QLGN alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Braeden Lichti

    (Last) (First) (Middle)
    5857 OWENS AVENUE, SUITE 300

    (Street)
    CARLSBAD CA 92008

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/08/2024
    3. Issuer Name and Ticker or Trading Symbol
    Qualigen Therapeutics, Inc. [ QLGN ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Braeden Lichti 10/17/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $QLGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $QLGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QLGN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Qualigen Therapeutics Inc.

      10-Q - Qualigen Therapeutics, Inc. (0001460702) (Filer)

      7/21/25 5:27:03 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)

      7/16/25 9:28:08 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Qualigen Therapeutics Inc.

      10-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)

      6/30/25 5:28:36 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QLGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Qualigen Granted New Patents Covering 25 Countries

      CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company" or "Qualigen") is announcing an update on patents granted in the first six months of 2025. The patent is Titled "Substitued Naphthalene Diimides and Their Use." The patent is for the drug, which was developed by Professor Stephen Neidle and his team at the University College of London, and is licensed by Qualigen Therapeutics, QN-302. These patents cover the product and their methods of manufacturing. Through validations and process across Europe these patents were granted and cover the majority of the Euoprean population. In total over 20 countries in Europe have patent coverage f

      7/16/25 8:00:00 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

      CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on May 19, 2025 (the "Notice"). The Notice indicated that the Nasdaq Hearings Panel (the "Panel") will consider the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 as an additional basis for delisting the Company's securities from The Nasdaq Stock Market. This matter serves as an additional deficiency under Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all

      5/19/25 5:25:00 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

      CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on April 24, 2025 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c) (the "Listing Rule") as a result of its failure to timely file its Annual Report on Form 10-K for the annual period ended December 31, 2024 (the "2024 Form 10-K"), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the "Form 12b-25") filed with the Securities and Exchange Co

      5/1/25 4:20:00 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QLGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Bensler Graydon

      3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

      11/15/24 4:05:33 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Braeden Lichti

      3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

      10/17/24 4:05:15 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Lim Robert Bradley

      3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

      8/9/24 4:01:09 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QLGN
    Financials

    Live finance-specific insights

    See more
    • Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

      Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately $5 million in all cash transaction to support advancement of therapeutics pipeline CARLSBAD, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces financial results for the second quarter ending June 30, 2023, and provides a corporate update: Highlights For Second Quarter and To Date 2023: Therapeutics Highlights: QN-

      8/15/23 8:30:00 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023

      Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the first quarter ending March 31, 2023, and provides a corporate update. Highlights For First Quarter and To Date 2023: Therapeutics Highlights: QN-302 Orphan Drug Designation granted by FDA for the intended indication of pancreatic cancerGood laboratory practice (GLP) toxicology studies initiatedComposition

      5/16/23 8:00:00 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

      CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN, Inc.))), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the fourth quarter and fiscal year ended December 31, 2022, and provides an update on the company's therapeutics pipeline and other corporate developments. Highlights For 2022 and to Date: Therapeutics Highlights: QN-302 Secured worldwide rights to G4-selective transcription inhibitors from University College London to develop as cancer therapeuticsEngaged QN

      5/2/23 4:30:00 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QLGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Qualigen Therapeutics, Inc. Announces management changes.

      CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives. On September 25, 2024, the board of directors appointed Campbell Becher as President of the

      9/26/24 5:10:00 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

      CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that it has appointed Shishir Sinha, the Company's newly promoted Senior Vice President and current Chief Operating Officer, to lead the Company's diagnostics division. "Shishir's consistent leadership as chief operating officer has been an essential part of our strategy to date. With the return of the sales and marketing of FastPack® last month, our diagnostics business is an essential asset to t

      4/29/22 9:15:00 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer

      New Position Created to Deepen Clinical Expertise and Advance Pipeline Therapeutic Programs CARLSBAD, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, today announced the appointment of Tariq Arshad, MD, MBA to the newly-created position of Senior Vice President, Chief Medical Officer. Dr. Arshad brings more than 20 years of biotech and pharmaceutical experience to Qualigen Therapeutics during a dynamic time of growth and implementation of long-range strategy. "We are delighted to welcome Tariq to Qualigen as our Chief Medical Off

      5/19/21 7:30:00 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QLGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Qualigen Therapeutics Inc. (Amendment)

      SC 13G/A - Qualigen Therapeutics, Inc. (0001460702) (Subject)

      5/27/22 9:22:10 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Qualigen Therapeutics, Inc.

      SC 13G - Qualigen Therapeutics, Inc. (0001460702) (Subject)

      12/6/21 5:04:28 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care